Breaking News Instant updates and real-time market news.

RHHBY

Roche

$0.00

(0.00%)

05:37
10/15/18
10/15
05:37
10/15/18
05:37

Genentech says Phase III KATHERINE study met primary endpoint

Genentech, a member of the Roche Group, announced the Phase III KATHERINE study met its primary endpoint, showing Kadcyla as a single agent significantly reduced the risk of disease recurrence or death compared to Herceptin as an adjuvant treatment in people with HER2-positive early breast cancer, or EBC, who have residual disease present following neoadjuvant treatment. The safety profile of Kadcyla in the KATHERINE study was consistent with previous clinical trials and no new safety signals were identified. The KATHERINE trial investigated a population of people with HER2-positive EBC who did not achieve a pathological complete response to neoadjuvant treatment. This state of residual disease is associated with a worse prognosis. The goal in treating early breast cancer is to provide people with the best chance for a cure. While we come closer to this goal with each advance, many people still have a disease recurrence in the long-term. Neoadjuvant treatment is given before surgery with the goal of shrinking tumors and helping to improve surgical outcomes. Adjuvant treatment is given after surgery as part of a complete EBC treatment regimen and is aimed at eliminating any remaining cancer cells in the body to help reduce the risk of the cancer returning.

  • 16

    Oct

  • 19

    Oct

  • 07

    Nov

  • 24

    Dec

RHHBY Roche
$0.00

(0.00%)

09/21/18
PIPR
09/21/18
NO CHANGE
Target $400
PIPR
Overweight
Biogen upcoming BIIB098 data an overlooked catalyst, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond believes investor sentiment on Biogen (BIIB) overlooks the H2H tolerability data for BIIB098 versus Tecfidera coming in the first half of 2018 Though BIIB098 is largely discounted as an intellectual property play "or worse," the readout, if positive, may be an important catalyst ahead of FDA approval in Q4 of 2019, Raymond tells investors in a research note. He suspects that if BIIB098 shows meaningful tolerability improvement over Tecfidera, "docs will likely take notice." Further, Raymond's new neurologist survey indicates that while the launch trends of Roche's (RHHBY) multiple sclerosis drugOcrevus "appear to be improving," other share trends, including those for Tecfidera and Tysabri, "remain stable." The analyst keeps an Overweight rating on Biogen with a $400 price target.
10/03/18
PIPR
10/03/18
NO CHANGE
PIPR
Overweight
PTC, Roche data add uncertainty to Biogen drug outlook, says Piper Jaffray
The risdiplam spinal muscular atrophy data released this morning by PTC Therapeutic (PTCT) and Roche (RHHBY) stack up fairly well to Biogen's (BIIB) Spinraza clinical data, Piper Jaffray analyst Christopher Raymond tells investors in a research note. Even taking into account all of the usual caveats regarding cross-trial comparisons, risdiplam is shaping up well compared to Spinraza, the analyst contends. He sees the new data as adding uncertainty to the Spinraza trajectory. Nonetheless, Raymond keeps an Overweight rating on shares of Biogen. The analyst made no changes to his Biogen model, but he admits risdiplam, if the data holds up, may impact Spinraza's ultimate market potential. Biogen in midday trading is up 2% to $351.41.
10/03/18
BARD
10/03/18
NO CHANGE
Target $348
BARD
Neutral
Risdiplam data incrementally negative for Biogen, says Baird
Biogen analyst Brian Skorney views this morning's risdiplam data for use in treating spinal muscular atrophy patients as incrementally negative for Biogen (BIIB). The data from PTC Therapeutics (PTCT) and PTC Therapeutics (RHHBY) are compelling so far, and suggest that risdiplam could impact the market share of Biogen's Spinraza, if it comes to market, Skorney tells investors in a research note. He highlights risdiplam's convenience as an oral small molecule and says the Phase II data "continues to impress." The analyst keeps a Neutral rating on Biogen with a $348 price target. The stock in afternoon trading is up $6.90, or 2%, to $352.31.
10/08/18
SBSH
10/08/18
NO CHANGE
Target $470
SBSH
Buy
Biogen price target lowered to $470 from $483 at Citi
Citi analyst Robyn Karnauskas lowered her price target for Biogen (BIIB) to $470 after reducing her assumptions for Rituxan/Gazyva co-promotion profits to reflect greater erosion from biosimilar versions of Rituxan that are expected to launch late 2018/early 2019. The analyst points out that consensus estimates are not modeling significant co-promotion profit erosion from Rituxan biosimilars. However, the Roche (RHHBY) consensus for Rituxan has steep declines in Rituxan sales, Karnauskas tells investors in a research note. The analyst now models a 45% total decline in Rituxan/Gazyva U.S. sales over 2018-2023. She keeps a Buy rating on Biogen.

TODAY'S FREE FLY STORIES

BIIB

Biogen

$223.57

3.52 (1.60%)

08:31
10/22/19
10/22
08:31
10/22/19
08:31
Recommendations
Biogen analyst commentary  »

RBC says Biogen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

SYF

Synchrony

$35.06

0.74 (2.16%)

, DKS

Dick's Sporting

$40.21

0.41 (1.03%)

08:31
10/22/19
10/22
08:31
10/22/19
08:31
Hot Stocks
Synchrony extends agreement with Dick's Sporting »

Synchrony (SYF) announced…

SYF

Synchrony

$35.06

0.74 (2.16%)

DKS

Dick's Sporting

$40.21

0.41 (1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

MU

Micron

$45.25

1.78 (4.09%)

, SSNLF

Samsung

$0.00

(0.00%)

08:30
10/22/19
10/22
08:30
10/22/19
08:30
Recommendations
Micron, Samsung analyst commentary  »

Bernstein sees signs of…

MU

Micron

$45.25

1.78 (4.09%)

SSNLF

Samsung

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 30

    Oct

  • 06

    Nov

  • 20

    Nov

DT

Dynatrace

$18.27

0.325 (1.81%)

08:30
10/22/19
10/22
08:30
10/22/19
08:30
Options
One new option listing on October 22nd »

New option listings for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 19

    Nov

08:29
10/22/19
10/22
08:29
10/22/19
08:29
Conference/Events
Washington Journal holds discussion on impeachment inquiry »

Georgetown University Law…

ZION

Zions Bancorp

$45.68

0.96 (2.15%)

08:28
10/22/19
10/22
08:28
10/22/19
08:28
Recommendations
Zions Bancorp analyst commentary  »

Zions Bancorp price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUB

Atlantic Union Bankshares

$37.59

-0.09 (-0.24%)

08:27
10/22/19
10/22
08:27
10/22/19
08:27
Hot Stocks
Atlantic Union Bankshares announces new equipment finance division »

Atlantic Union Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Nov

  • 13

    Nov

  • 10

    Dec

GDP

Goodrich Petroleum

$9.80

0.27 (2.83%)

08:26
10/22/19
10/22
08:26
10/22/19
08:26
Recommendations
Goodrich Petroleum analyst commentary  »

Goodrich Petroleum price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

OBLN

Obalon Therapeutics

$1.88

0.085 (4.74%)

08:26
10/22/19
10/22
08:26
10/22/19
08:26
Hot Stocks
Obalon Therapeutics announces first patient treaments at center for weight loss »

Obalon Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJT

DJ Transportation Average

$0.00

(0.00%)

08:24
10/22/19
10/22
08:24
10/22/19
08:24
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJU

DJ Utility Average

$0.00

(0.00%)

08:24
10/22/19
10/22
08:24
10/22/19
08:24
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNET

RigNet

$6.10

(0.00%)

08:24
10/22/19
10/22
08:24
10/22/19
08:24
Hot Stocks
RigNet opens new office in Lafayette, Louisiana metropolitan area »

RigNet announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

08:24
10/22/19
10/22
08:24
10/22/19
08:24
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYT

iShares Transportation Average

$191.26

2.49 (1.32%)

08:24
10/22/19
10/22
08:24
10/22/19
08:24
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$81.76

0.85 (1.05%)

08:23
10/22/19
10/22
08:23
10/22/19
08:23
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STMP

Stamps.com

$76.12

0.55 (0.73%)

, UPS

UPS

$118.56

1.23 (1.05%)

08:23
10/22/19
10/22
08:23
10/22/19
08:23
Recommendations
Stamps.com, UPS analyst commentary  »

Stamps.com price target…

STMP

Stamps.com

$76.12

0.55 (0.73%)

UPS

UPS

$118.56

1.23 (1.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Oct

  • 07

    Nov

XLE

Energy Select Sector SPDR

$58.07

1.04 (1.82%)

08:23
10/22/19
10/22
08:23
10/22/19
08:23
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLY

Consumer Discretionary Sector SPDR

$122.63

0.45 (0.37%)

08:23
10/22/19
10/22
08:23
10/22/19
08:23
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

XLB

S&P Select Materials SPDR

$57.34

-0.19 (-0.33%)

08:23
10/22/19
10/22
08:23
10/22/19
08:23
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPLK

Splunk

$111.11

0.13 (0.12%)

08:23
10/22/19
10/22
08:23
10/22/19
08:23
Hot Stocks
Splunk Cloud receives FedRAMP authorization »

Splunk announced Splunk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLU

Utilities SPDR

$64.06

0.24 (0.38%)

08:22
10/22/19
10/22
08:22
10/22/19
08:22
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$60.93

0.18 (0.30%)

08:22
10/22/19
10/22
08:22
10/22/19
08:22
Technical Analysis
Consumer Staples Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLV

Health Care Select Sector SPDR

$91.69

-0.08 (-0.09%)

08:22
10/22/19
10/22
08:22
10/22/19
08:22
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$154.05

1.42 (0.93%)

08:22
10/22/19
10/22
08:22
10/22/19
08:22
Technical Analysis
iShares Trust Russell 2000 Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIA

Diamonds Fund ETF

$268.21

0.58 (0.22%)

08:21
10/22/19
10/22
08:21
10/22/19
08:21
Technical Analysis
Diamonds Fund ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.